Phaseline

Companies › Vogenx

Vogenx: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Metabolic and endocrine; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Mizagliflozin 5 mg
SGLT1 inhibitor
SLC5A1Phase 2Postbariatric HypoglycemiaOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07760961Mizagliflozin 5 mgPhase 2Postbariatric HypoglycemiaMetabolic and endocrineOct 2027
NCT07760961Mizagliflozin 5 mgPhase 2Postbariatric HypoglycemiaMetabolic and endocrineOct 2027

From the company's SEC filings

Cash and short-term investments of $82m on 2026-09-30; operating cash outflow about $4m a year; runway about 252 months at that burn, to Sep 2047; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

SLC5A1 (1)

Companies with the same targets

Lexicon Pharmaceuticals Colgate Palmolive

Companies built like this

Lexicon Pharmaceuticals vTv Therapeutics SAb Biotherapeutics Amorphical ERX Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.